New insights into complement: a mediator of injury and marker of disease activity in systemic lupus erythematosus

被引:16
作者
Manzi, S
Ahearn, JM
Salmon, J
机构
[1] Univ Pittsburgh, Sch Med, Lupus Ctr Excellence, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA
[3] Cornell Univ, Weill Med Coll, Hosp Special Surg, Mary Kirkland Ctr Lupus Res, New York, NY USA
关键词
complement; complement activation; complement receptor 1; lupus activity; pregnancy;
D O I
10.1191/0961203303lu1016oa
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Studies performed during the past several decades have demonstrated a role for the complement system in both the etiology and pathogenesis of systemic lupus erythematosus (SLE). However the specifically defective molecular and cellular pathways responsible for the disease and its complications have generally not been identified. In this report, we describe two recent advances in complement pathobiology that highlight future directions for promising investigation toward enhancing our capacity to diagnose SLE, to monitor activity of the disease, and to identify molecular and cellular defects in SLE that can be targeted by therapeutic inhibitors of complement activation. In the first example, we describe recently developed assays to detect erythrocyte C4d and complement receptor 1 for diagnosis and monitoring of disease activity in SLE. In the second example, we describe a recently discovered role for complement in mediating fetal loss in antiphospholipid syndrome and discuss the potential for this observation to facilitate identification and development of complement based biomarkers to predict poor fetal outcome in pregnant patients with SLE. These two examples are meant to underscore the importance of complement in the etiology and pathogenesis of SLE and its complications, and to stress the need for further investigation focused on the link between the complement system and SLE.
引用
收藏
页码:298 / 303
页数:6
相关论文
共 57 条
[1]   CORRELATION AND PREDICTIVE ACCURACY OF CIRCULATING IMMUNE-COMPLEXES WITH DISEASE-ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
ABRASS, CK ;
NIES, KM ;
LOUIE, JS ;
BORDER, WA ;
GLASSOCK, RJ .
ARTHRITIS AND RHEUMATISM, 1980, 23 (03) :273-282
[2]   STUDIES OF IN VIVO BEHAVIOR OF HUMAN C'3 IN NORMAL SUBJECTS AND PATIENTS [J].
ALPER, CA ;
ROSEN, FS .
JOURNAL OF CLINICAL INVESTIGATION, 1967, 46 (12) :2021-&
[3]   ORIGIN OF THE 4TH COMPONENT OF COMPLEMENT RELATED CHIDO AND RODGERS BLOOD-GROUP ANTIGENS [J].
ATKINSON, JP ;
CHAN, AC ;
KARP, DR ;
KILLION, CC ;
BROWN, R ;
SPINELLA, D ;
SHREFFLER, DC ;
LEVINE, RP .
COMPLEMENT, 1988, 5 (02) :65-76
[4]   Rheumatic syndromes associated with complement deficiency [J].
Barilla-LaBarca, ML ;
Atkinson, JP .
CURRENT OPINION IN RHEUMATOLOGY, 2003, 15 (01) :55-60
[5]   The role of complement in inflammation and adaptive immunity [J].
Barrington, R ;
Zhang, M ;
Fischer, M ;
Carroll, MC .
IMMUNOLOGICAL REVIEWS, 2001, 180 :5-15
[6]   COMPLEMENT ACTIVATION DURING SYSTEMIC LUPUS-ERYTHEMATOSUS - C3A AND C5A ANAPHYLATOXINS CIRCULATE DURING EXACERBATIONS OF DISEASE [J].
BELMONT, HM ;
HOPKINS, P ;
EDELSON, HS ;
KAPLAN, HB ;
LUDEWIG, R ;
WEISSMANN, G ;
ABRAMSON, S .
ARTHRITIS AND RHEUMATISM, 1986, 29 (09) :1085-1089
[7]   ACTIVATION OF THE ALTERNATIVE COMPLEMENT PATHWAY ACCOMPANIES DISEASE FLARES IN SYSTEMIC LUPUS-ERYTHEMATOSUS DURING PREGNANCY [J].
BUYON, JP ;
TAMERIUS, J ;
ORDORICA, S ;
YOUNG, B ;
ABRAMSON, SB .
ARTHRITIS AND RHEUMATISM, 1992, 35 (01) :55-61
[8]   ASSESSMENT OF DISEASE-ACTIVITY AND IMPENDING FLARE IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS - COMPARISON OF THE USE OF COMPLEMENT SPLIT PRODUCTS AND CONVENTIONAL MEASUREMENTS OF COMPLEMENT [J].
BUYON, JP ;
TAMERIUS, J ;
BELMONT, HM ;
ABRAMSON, SB .
ARTHRITIS AND RHEUMATISM, 1992, 35 (09) :1028-1037
[9]   SERUM COMPLEMENT VALUES (C-3 AND C-4) TO DIFFERENTIATE BETWEEN SYSTEMIC LUPUS ACTIVITY AND PREECLAMPSIA [J].
BUYON, JP ;
CRONSTEIN, BN ;
MORRIS, M ;
TANNER, M ;
WEISSMANN, G .
AMERICAN JOURNAL OF MEDICINE, 1986, 81 (02) :194-200
[10]  
CAMERON JS, 1976, CLIN EXP IMMUNOL, V25, P418